| ABD | agonist-binding domain |
| AD | Alzheimer’s disease |
| AMPAR | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
| Aβ | amyloid-β |
| BDNF | brain-derived neurotrophic factor |
| CaMKII | camodulin kinase II |
| cAMP | 3′,5′-adenosine monophosphate |
| cGMP | 3′,5′-guanosine monophosphate |
| CNS | central nervous system |
| CREB | cAMP response element-binding protein |
| CTD | carboxyl C-terminal domain |
| DYRK1A | dual-specificity tyrosine-phosphorylation-regulated kinase 1 |
| EAAT | excitatory amino acid transporter |
| ERK1/2 | extracellular signal-regulated protein kinase 1/2 |
| FENM | fluoroethylnormemantine |
| GABA | γ-aminobutyric acid |
| HD | Huntington’s disease |
| HEK-293 | human embryonic kidney 293 cells |
| L-Dopa | L-3,4-dihydroxyphenylalanine |
| LTD | long-term depression |
| LTP | long-term potentiation |
| MAPK | mitogen-activated protein kinases |
| NMDAR | N-methyl-d-aspartate receptor |
| PCP | phencycline |
| PD | Parkinson’s disease |
| PET | positron emission tomography |
| PKA | protein kinase A |
| PSD-95 | post-synaptic density protein 95 |
| PTSD | post-traumatic stress disorder |
| RCPG | G protein-coupled receptor |
| SANT | sodium-coupled neutral amino acid transporter |
| tPA | tissue-type plasminogen activator |